1. Home
  2. PHAT vs HAFC Comparison

PHAT vs HAFC Comparison

Compare PHAT & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • HAFC
  • Stock Information
  • Founded
  • PHAT 2018
  • HAFC 1982
  • Country
  • PHAT United States
  • HAFC United States
  • Employees
  • PHAT N/A
  • HAFC N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • HAFC Major Banks
  • Sector
  • PHAT Health Care
  • HAFC Finance
  • Exchange
  • PHAT Nasdaq
  • HAFC Nasdaq
  • Market Cap
  • PHAT 727.5M
  • HAFC 708.5M
  • IPO Year
  • PHAT 2019
  • HAFC 1996
  • Fundamental
  • Price
  • PHAT $9.80
  • HAFC $24.63
  • Analyst Decision
  • PHAT Strong Buy
  • HAFC Buy
  • Analyst Count
  • PHAT 5
  • HAFC 6
  • Target Price
  • PHAT $16.40
  • HAFC $25.75
  • AVG Volume (30 Days)
  • PHAT 4.9M
  • HAFC 131.2K
  • Earning Date
  • PHAT 08-07-2025
  • HAFC 07-22-2025
  • Dividend Yield
  • PHAT N/A
  • HAFC 4.38%
  • EPS Growth
  • PHAT N/A
  • HAFC N/A
  • EPS
  • PHAT N/A
  • HAFC 2.13
  • Revenue
  • PHAT $81,859,000.00
  • HAFC $231,876,000.00
  • Revenue This Year
  • PHAT $195.45
  • HAFC $17.80
  • Revenue Next Year
  • PHAT $106.76
  • HAFC $7.22
  • P/E Ratio
  • PHAT N/A
  • HAFC $11.59
  • Revenue Growth
  • PHAT 3055.70
  • HAFC N/A
  • 52 Week Low
  • PHAT $2.21
  • HAFC $15.74
  • 52 Week High
  • PHAT $19.71
  • HAFC $27.59
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 66.25
  • HAFC 64.72
  • Support Level
  • PHAT $8.86
  • HAFC $22.40
  • Resistance Level
  • PHAT $11.21
  • HAFC $23.75
  • Average True Range (ATR)
  • PHAT 1.59
  • HAFC 0.63
  • MACD
  • PHAT -0.06
  • HAFC 0.14
  • Stochastic Oscillator
  • PHAT 63.60
  • HAFC 97.44

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: